Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 209

1.

Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients.

Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS.

Cancer Res. 2009 Sep 1;69(17):6889-98. doi: 10.1158/0008-5472.CAN-09-0347. Epub 2009 Aug 18.

2.

Lyn kinase mediates cell motility and tumor growth in EGFRvIII-expressing head and neck cancer.

Wheeler SE, Morariu EM, Bednash JS, Otte CG, Seethala RR, Chiosea SI, Grandis JR.

Clin Cancer Res. 2012 May 15;18(10):2850-60. doi: 10.1158/1078-0432.CCR-11-2486. Epub 2012 Apr 6.

3.

Phosphorylation of dedicator of cytokinesis 1 (Dock180) at tyrosine residue Y722 by Src family kinases mediates EGFRvIII-driven glioblastoma tumorigenesis.

Feng H, Hu B, Jarzynka MJ, Li Y, Keezer S, Johns TG, Tang CK, Hamilton RL, Vuori K, Nishikawa R, Sarkaria JN, Fenton T, Cheng T, Furnari FB, Cavenee WK, Cheng SY.

Proc Natl Acad Sci U S A. 2012 Feb 21;109(8):3018-23. doi: 10.1073/pnas.1121457109. Epub 2012 Feb 7.

4.

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma.

Girotti MR, Pedersen M, Sanchez-Laorden B, Viros A, Turajlic S, Niculescu-Duvaz D, Zambon A, Sinclair J, Hayes A, Gore M, Lorigan P, Springer C, Larkin J, Jorgensen C, Marais R.

Cancer Discov. 2013 Feb;3(2):158-67. doi: 10.1158/2159-8290.CD-12-0386. Epub 2012 Dec 14.

5.
6.

Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.

Hu J, Muller KA, Furnari FB, Cavenee WK, VandenBerg SR, Gonias SL.

Oncogene. 2015 Jul 30;34(31):4078-88. doi: 10.1038/onc.2014.336. Epub 2014 Oct 27.

7.

Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways.

Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, Ang KK.

Radiother Oncol. 2012 Nov;105(2):241-9. doi: 10.1016/j.radonc.2012.08.010. Epub 2012 Sep 23.

PMID:
23010482
8.

Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells.

Lin YC, Wu MH, Wei TT, Chuang SH, Chen KF, Cheng AL, Chen CC.

Neoplasia. 2012 Jun;14(6):463-75.

9.

Src family kinases differentially influence glioma growth and motility.

Lewis-Tuffin LJ, Feathers R, Hari P, Durand N, Li Z, Rodriguez FJ, Bakken K, Carlson B, Schroeder M, Sarkaria JN, Anastasiadis PZ.

Mol Oncol. 2015 Nov;9(9):1783-98. doi: 10.1016/j.molonc.2015.06.001. Epub 2015 Jun 10.

10.

Targeting Src family kinases inhibits bevacizumab-induced glioma cell invasion.

Huveldt D, Lewis-Tuffin LJ, Carlson BL, Schroeder MA, Rodriguez F, Giannini C, Galanis E, Sarkaria JN, Anastasiadis PZ.

PLoS One. 2013;8(2):e56505. doi: 10.1371/journal.pone.0056505. Epub 2013 Feb 14.

11.

Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.

Rao S, Larroque-Lombard AL, Peyrard L, Thauvin C, Rachid Z, Williams C, Jean-Claude BJ.

PLoS One. 2015 Feb 6;10(2):e0117215. doi: 10.1371/journal.pone.0117215. eCollection 2015.

12.

The TWEAK Receptor Fn14 Is an Src-Inducible Protein and a Positive Regulator of Src-Driven Cell Invasion.

Cheng E, Whitsett TG, Tran NL, Winkles JA.

Mol Cancer Res. 2015 Mar;13(3):575-83. doi: 10.1158/1541-7786.MCR-14-0411. Epub 2014 Nov 12.

13.

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

Lal B, Goodwin CR, Sang Y, Foss CA, Cornet K, Muzamil S, Pomper MG, Kim J, Laterra J.

Mol Cancer Ther. 2009 Jul;8(7):1751-60. doi: 10.1158/1535-7163.MCT-09-0188. Epub 2009 Jul 7.

14.

EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation.

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, Fritah S, Harter PN, Välk K, Al Hossain J, Joseph JV, Jahedi R, Saed HS, Piccirillo SG, Spiteri I, Leiss L, Euskirchen P, Graziani G, Daubon T, Lund-Johansen M, Enger PØ, Winkler F, Ritter CA, Niclou SP, Watts C, Bjerkvig R, Miletic H.

Neuro Oncol. 2016 Dec;18(12):1644-1655. Epub 2016 Jun 10. Erratum in: Neuro Oncol. 2016 Dec;18(12 ):e2.

PMID:
27286795
15.

Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells.

Buettner R, Mesa T, Vultur A, Lee F, Jove R.

Mol Cancer Res. 2008 Nov;6(11):1766-74. doi: 10.1158/1541-7786.MCR-08-0169.

16.

SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.

Leung EL, Tam IY, Tin VP, Chua DT, Sihoe AD, Cheng LC, Ho JC, Chung LP, Wong MP.

Mol Cancer Res. 2009 Jun;7(6):923-32. doi: 10.1158/1541-7786.MCR-09-0003. Epub 2009 Jun 2.

17.

Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.

Kim EM, Mueller K, Gartner E, Boerner J.

J Surg Res. 2013 Nov;185(1):231-9. doi: 10.1016/j.jss.2013.06.041. Epub 2013 Jul 17.

PMID:
23899511
18.

Deficiency of Fyn protein is prerequisite for apoptosis induced by Src family kinase inhibitors in human mesothelioma cells.

Eguchi R, Kubo S, Takeda H, Ohta T, Tabata C, Ogawa H, Nakano T, Fujimori Y.

Carcinogenesis. 2012 May;33(5):969-75. doi: 10.1093/carcin/bgs109. Epub 2012 Feb 21.

PMID:
22354875
19.

Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab.

Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, Harari PM.

Cancer Biol Ther. 2009 Apr;8(8):696-703. Epub 2009 Apr 22.

20.

Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification.

Yoshida T, Okamoto I, Okamoto W, Hatashita E, Yamada Y, Kuwata K, Nishio K, Fukuoka M, Jänne PA, Nakagawa K.

Cancer Sci. 2010 Jan;101(1):167-72. doi: 10.1111/j.1349-7006.2009.01368.x. Epub 2009 Sep 14.

Supplemental Content

Support Center